13 Feb CUTISS
Posted at 19:25h
in
Daniela Marino, Ph.D., CEO
April 15 | 9:45am | Salone dei Cavalieri, Section 2
Schlieren, Switzerland
(Private)
We are a Swiss biotech leader in skin regenerative medicine. Our first focus is to provide patients who suffer from large skin injuries and defects with personalized skin tissue therapy in a safe, effective and accessible manner via a proprietary automation platform. We are in phase 3 clinical trials. 50 FTE, 100m$ raised to date.
